AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04014426 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urinary sample
Description: Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)
Study NCT02604459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebral oximeter (Fore-Sight)
Description: The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
Study NCT02604459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: depth of anesthesia monitor (BIS)
Description: The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
Study NCT02604459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BP management
Description: The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
Study NCT01550744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Form = Injection, route = subcutaneous
Study NCT01550744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Form = Injection, route = subcutaneous
Study NCT02604459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be used in both groups
Study NCT02604459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia will be used in both groups
Study NCT01550744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form = Injection, route = subcutaneous
Study NCT03716245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supraclavicular lymph node dissection
Description: people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
Study NCT03716245 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular area radiotherapy
Description: people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
Study NCT03678324 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI and fast bound-pool fraction imaging
Description: Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey.
Study NCT02523196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)
Description: The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
Study NCT02523196 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hepatic Venous Pressure Gradient (HVPG)
Description: Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
Study NCT02468492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma injection into knee versus placebo (saline) injection.
Study NCT02604459 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anesthesia
Description: General anesthesia will be used in both groups
Study NCT02468492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: Platelet rich plasma injection into knee versus placebo (saline) injection.
Study NCT03570086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic
Description: using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol per protocol
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol per protocol
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol
Description: propofol per protocol
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl per protocol
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: fentanyl per protocol
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl
Description: fentanyl per protocol
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: maintenance of anesthesia with inhaled sevoflurane
Study NCT00677079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Body weight adjusted dose~1 hour intravenous infusion
Study NCT00222352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care cTnL testing
Description: The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half.
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: maintenance of anesthesia with inhaled sevoflurane
Study NCT02604459 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane
Description: maintenance of anesthesia with inhaled sevoflurane
Study NCT04478903 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Zarit Burden Inventory French version and SF12
Study NCT06290518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ligilactobacillus salivarius CECT5713
Description: Oral administration of a capsule containing 9.5 log10 cfu of the strain.
Study NCT04537741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography
Description: all patients being included will undergo CCTA before invasive coronary angiography
Study NCT04537741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography
Description: all patients being included will undergo CCTA before invasive coronary angiography
Study NCT01138475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 1 microgram by mouth daily for 6 weeks
Study NCT01138475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 5000 IU (international units) by mouth daily for 6 weeks
Study NCT06290518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of a capsule containing maltodextrin.
Study NCT01138475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance, one capsule daily for 6 weeks
Study NCT02423486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation therapy (BIOCON-2000)
Study NCT02423486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation therapy with biofeedback
Study NCT02373618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DN and conventional PT
Description: Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
Study NCT02373618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
Study NCT04344730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
Study NCT04344730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
Study NCT04344730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
Study NCT04344730 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional oxygen
Description: The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
Study NCT04344730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional oxygen
Description: The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
Study NCT04344730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
Study NCT04344730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
Study NCT03325465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
Study NCT03325465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
Study NCT03161548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14
Study NCT04344730 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: mechanical ventilation
Description: The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
Study NCT04344730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
Study NCT03907397 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Protein
Description: up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)
Study NCT03907397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continued peanut avoidance
Description: Standard of care avoidance of peanut
Study NCT02448134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Access
Description: Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
Study NCT01387750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mentholated Cream
Description: A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
Study NCT01387750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mentholated Cream with OGT
Description: A Topical Cream that contained both menthol and oxygenated glycerol triesters.
Study NCT01560221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Workplace
Description: Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
Study NCT01560221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
Study NCT01560221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
Study NCT02132403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTH1704
Description: BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
Study NCT02132403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPRIME PGG
Description: Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
Study NCT01560221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
Study NCT02132403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
Study NCT03767543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study NCT03767543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study NCT01791517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solution 1 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
Study NCT01791517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solution 2 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
Study NCT01560221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
Study NCT02636920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Education to the Patient (TEP)
Description: * Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~* Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~* Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~* Assessing of the knowledges acquired by patients.
Study NCT01791517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solution 3 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
Study NCT01791517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solution 4 (Control)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
Study NCT04595786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
Study NCT04595786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline was prepared in a 50ml syringe for intravenous pump
Study NCT03767257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam Pill
Description: For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
Study NCT03161548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue conservation surgery
Description: Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
Study NCT03161548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative CCRT
Description: Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy
Study NCT02478320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilorasertib
Description: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
Study NCT03286478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
Study NCT03962855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifetroban Sodium
Description: Ifetroban sodium 250 mg capsule once daily for 4 weeks
Study NCT03962855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
Study NCT00565409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Subcutaneous (SC), 50 mg, once weekly for 88 weeks
Study NCT00565409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).
Study NCT00565409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
Study NCT00565409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC), once weekly from week 36 to week 88.